Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Antiplatelet therapy

Eptifibatide is noninferior to abciximab: implications for clinical practice

Nature Reviews Cardiology volume 7, page 539 (2010)Cite this article

Subjects

Access through your institution
Buy or subscribe

The glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors eptifibatide and abciximab have comparable efficacy and safety in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). These findings, from a randomized trial and a registry study, are reported in two papers published in the Journal of the American College of Cardiology (JACC).

The EVA-AMI trial, reported by Uwe Zeymer and colleagues, was a prospective, randomized, open, parallel-group comparison of eptifibatide and abciximab in 427 patients presenting within 12 h of STEMI onset and who underwent primary PCI. Enrolled patients were from 22 centers in France and Germany. The two study drugs were administered in combination with background therapy comprising clopidogrel, aspirin, and heparin or enoxaparin. This study used the surrogate primary end point of complete electrocardiographic ST-segment resolution (STR) 60 min after completion of PCI.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPERS

  1. Zeymer, U. et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J. Am. Coll. Cardiol. 56, 463–469 (2010)

    Article  CAS  Google Scholar 

  2. Åkerblom, A. et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J. Am. Coll. Cardiol. 56, 470–475 (2010)

    Article  Google Scholar 

Download references

Authors
  1. Alexandra King
    View author publications

    You can also search for this author inPubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

King, A. Eptifibatide is noninferior to abciximab: implications for clinical practice. Nat Rev Cardiol 7, 539 (2010). https://doi.org/10.1038/nrcardio.2010.128

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.128

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing